News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.
Photo taken from Rami Manochakian/Twitter
Oct 4, 2023, 17:57

Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.

Rami Manochakian, Associate Professor and Hematology/Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:

“Hot off the press.

Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative Exclaim2 trial.”

 

Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.

For deteils click here.
Source: Rami Manochakian/Twitter

cancer Lung cancer Mayo Clinic Mobocertinib OncoDaily Oncology Rami Manochakian
Special Coverage
Blog
Jan 19, 2025, 03:06
Yvonne Diaz: AI, wearables and digital tech in clinical research
Societies
Jan 18, 2025, 23:03
Abstract submission system open for the ESMO Gynaecological Cancers 2025
Science
Jan 18, 2025, 23:00
New training modules on pain management in cancer care - Society for Integrative Oncology
Blog
Jan 18, 2025, 22:58
Wafik S. El-Deiry: Honored to express a vision for the field of cancer research and innovation in oncology
Blog
Jan 18, 2025, 22:56
Herbert Loong: Philip Ip kicked off the 12th Hong Kong pathology forum
Insight
Jan 18, 2025, 22:55
Last days to apply for the ‘Improving Cancer Outcomes and Leadership’ course - ESO
Drugs
Jan 18, 2025, 22:55
Jean-Charles Soria: FDA approved 57 new therapeutic drugs in 2024
Blog
Jan 18, 2025, 22:54
Yakup Ergün: Patients' interests must always come first in clinical trials
Insight
Jan 18, 2025, 22:53
Breaking new ground in Blood Cancer research - The Leukemia and Lymphoma Society
Blog
Jan 18, 2025, 22:52
Yüksel Ürün: Florence Multidisciplinary Expert Meeting on Renal Cell Carcinoma
Blog
Jan 18, 2025, 22:50
Carmen Uscatu: How can I read the room?
Career
Jan 18, 2025, 22:48
Kristina Jankovic: I’ve been selected for the 2025 ESO mentorship program